Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
BACKGROUND
Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES).


METHODS
Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded.


RESULTS
Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ≥50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ≥50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES.


CONCLUSIONS
Abiraterone has important antitumour activity in men with CRPC even after DES exposure.
Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
A
A
Omlin
C J
CJ
Pezaro
S
S
Zaidi
D
D
Lorente
D
D
Mukherji
D
D
Bianchini
R
R
Ferraldeschi
S
S
Sandhu
D
D
Dearnaley
C
C
Parker
N
N
Van As
J S
JS
de Bono
G
G
Attard
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D018450:Disease Progression; D000077143:Docetaxel; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D000970:Antineoplastic Agents; D004968:Estrogens, Non-Steroidal; D043823:Taxoids; D000077143:Docetaxel; D004054:Diethylstilbestrol; C501892:CYP17A1 protein, human; D013254:Steroid 17-alpha-Hydroxylase; D017430:Prostate-Specific Antigen; C089740:abiraterone